C12N 2770/36151
Methods of production or purification of viral material
C12N2770/36151 (Methods of production or purification of viral material) appears on 54 US grants and 90 published applications in this corpus.
Search patents in C12N- Granted patents
- 54
- Published applications
- 90
- Assignees
- 47
- Inventors
- 146
- Latest grant
- 18 Feb 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 1 |
| 2002 | 2 | 3 |
| 2003 | 3 | 4 |
| 2004 | 2 | 7 |
| 2005 | 0 | 4 |
| 2006 | 4 | 2 |
| 2007 | 2 | 2 |
| 2008 | 2 | 4 |
| 2009 | 0 | 1 |
| 2010 | 0 | 2 |
| 2011 | 1 | 6 |
| 2012 | 0 | 2 |
| 2013 | 3 | 6 |
| 2014 | 2 | 5 |
| 2015 | 5 | 3 |
| 2016 | 4 | 7 |
| 2017 | 3 | 5 |
| 2018 | 2 | 1 |
| 2019 | 2 | 3 |
| 2020 | 5 | 2 |
| 2021 | 2 | 3 |
| 2022 | 0 | 2 |
| 2023 | 2 | 4 |
| 2024 | 2 | 4 |
| 2025 | 1 | 5 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Alphavirus replicon particle18 Feb 2025US 12,227,770 B2VLP Therapeutics, LLC
- Virus-like particles and methods of use17 Dec 2024US 12,168,675 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon30 Jul 2024US 12,049,639 B2The USA, as represented by the Secretary, Dept. of Health and Human Services
- Virus-like particles and methods of use8 Aug 2023US 11,718,647 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon8 Aug 2023US 11,718,861 B2The USA, as represented by the Secretary, Dept. of Health and Human Services
- Dna vaccine for fish against salmonid alphavirus27 Aug 2026US 2026/0248901 A1Intervet Inc.
- Virus-like vesicles (vlvs) based vaccines and methods of preventing, ameliorating, and/or treating covid-19 and/or hepatocellular carcinoma (hcc)5 Feb 2026US 2026/0034208 A1Yale University
- Virus-like particles and methods of use23 Oct 2025US 2025/0326801 A1The United States of America, as represented by the Secretary, Department of Health and Human Services
- Novel rna and dna technology for vaccination against alphaviruses and other emerging and epidemic viruses3 Jul 2025US 2025/0213671 A1Medigen, Inc.
- Methods for generating functional self-replicating rna molecules8 May 2025US 2025/0146038 A1Replicate Bioscience, Inc.
Most cited
By later US patents
- Alphavirus vectors and virosomes with modified HIV genes for use in vaccines101US 6,783,939 B2AlphaVax, Inc. · 2004
- Alphavirus RNA replicon systems100US 5,792,462 AThe United States of America as represented by the Secretary of the Army · 1998
- Alphavirus RNA replicon systems77US 6,156,558 AThe University of North Carolina at Chapel Hill · 2000
- Alphavirus replicon vector systems45US 7,045,335 B2AlphaVax, Inc. · 2006
- Alphavirus particles and methods for preparation42US 7,078,218 B2AlphaVax, Inc. · 2006